secwatch.observer — SEC 8-K summary
======================================

Issuer:     TriSalus Life Sciences, Inc. (TLSI)
CIK:        0001826667
Form:       8-K
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0001104659-23-117720
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TriSalus Q3 revenue $5.2M (+32% YoY); net loss $1.7M; PERIO-01 median PFS 11.7 months
--------------------------------------------------------------------------------

- Q3 revenue $5.2M, up 32% YoY; nine-month revenue $12.8M, up 39% YoY; gross margin 89%.
- Operating loss $18.5M (incl. $4.8M deSPAC costs); net loss $1.7M; diluted EPS loss $0.13.
- PERIO-01 Phase 1 data: median PFS 11.7 months, DCR 81%, 1-year OS 86%.
- PERIO-03 initial safety/feasibility for pancreatic cancer; dose expansion with anti-PD-1 expected early 2024.
- Appointed Jodi Devlin as President, Commercial Operations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826667/000110465923117720/0001104659-23-117720-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826667/000110465923117720/tm2330637d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-117720

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer